30/06/2008 (Agence Europe) -As part of its review of the benefits and risks of prescribing non-steroidal anti-inflammatories of the coxib group, the European Medicines Agency (EMEA) recommended on Thursday 26 June that the product information of etoricoxib-containing medicines used in the treatment of the various forms of arthritis should be updated, to highlight the increased cardiovascular risk associated with this product. (O.J./transl.rt)